CG Oncology vs Molecular Partners
CGON and MOLN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CGON and MOLN compare
CG Oncology grew revenue faster over the last twelve months (184% versus −100% for Molecular Partners).
CG Oncology scores higher on the StockData Score (5 against 1 for Molecular Partners), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CGON | MOLN |
|---|---|---|
| Size and price | ||
| Market cap | $6.4B | – |
| Share price | $72.61 | $3.09 |
| Change, 1 year | 80.5% | −27.3% |
| Change, 5 years | – | −70.4% |
| Beta (5Y) | 1.41 | 0.90 |
| Employees | 142 | 34 |
| StockData Score | ||
| Total score | 5 (better) | 1 |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 3 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1044× | – |
| P/B | 6.5× | – |
| FCF yield | −2.9% | – |
| Growth | ||
| Revenue growth (TTM) | 184% (better) | −100% |
| Profitability | ||
| Operating margin | −4294% | – |
| Net margin | −3851% | – |
| FCF margin | −3068% | – |
| Return on equity | −28.3% | – |
| Return on invested capital | −2103% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −11.5× |
| Current ratio | 21.70 (better) | 7.27 |
| Altman Z-score | 68.83 | – |
| Piotroski F-score | 1 | – |
| Dividends and buybacks | ||
| Buyback yield | −7.6% | – |
| Shareholder yield | −7.6% | – |
| Ownership | ||
| Held by institutions | 106% | 8.9% |
| Held by insiders | 17.3% | 0.00% |
| Insider net buying, 12 months | $20.0M | – |
| Short interest, % of float | 12.6% | – |
Go deeper
- CGON stock overview
- CGON income statement
- CGON valuation and score
- MOLN stock overview
- MOLN income statement
- MOLN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.